ELİF ÇAĞLA ERDOĞAN TACAN, BÜŞRA NUR ÇATTIK
Acta Pharmaceutica Sciencia - 2025;63(4):764-788
Prostate cancer is a major male malignancy driven by androgen activity. Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists like Leuprorelin and Goserelin is Standard treatment. This retrospective study compared their effectiveness in lowering prostate specific antigen (PSA) levels. Data from 80 patients (Goserelin 3.6 mg n=21, Leuprorelin 11.25 mg n=9, Leuprorelin 22.5 mg n=50) treated between January 2014 and October 2024 at a university hospital were analyzed. PSA was measured at four time points, and clinical parameters such as Gleason score, smoking, family history, and metastasis were included. All treatments significantly reduced PSA, but differences between groups were not statistically significant (p=0.167). Although testosterone follow-up was inconsistent due to data limitations, a clear downward trend in testosterone levels was observed, indicating treatment-induced hormonal suppression. Despite variability, both agents proved effective. These findings support the continued use of either drug in ADT and highlight the need for prospective studies to explore longterm outcomes.
